Clinical Performance and Safety of the Optima Non-compliant Percutaneous Transluminal Coronary Angioplasty Balloon in Contemporary Percutaneous Coronary Intervention: A Multicenter Real-World Study.
5 affiliations
- 1Interventional Cardiology, Kailash Hospital, Greater Noida, IND.
- 2Cardiology, Smt. S.R. Mehta and Sir K.P. Cardiac Institute, Mumbai, IND.
- 3Interventional Cardiology, Suretech Hospital, Nagpur, IND.
- 4Interventional Cardiology, Intima Heart and Critical Care, Nagpur, IND.
- 5Cardiology, NKP Salve Institute of Medical Sciences and Research Centre and Lata Mangeshkar Hospital, Nagpur, IND.
Abstract
Background Non-compliant (NC) balloon catheters are widely used during percutaneous coronary intervention (PCI) for lesion preparation and stent optimization because they allow controlled high-pressure dilation. However, real-world clinical data describing the procedural performance and short-term clinical outcomes of NC balloon catheters across diverse patient and lesion characteristics remain limited. This study evaluated the observed procedural performance, device performance characteristics, and short-term clinical outcomes associated with the use of the Optima NC non-compliant percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (Translumina Therapeutics Private Limited, New Delhi, India) during routine PCI. Methods This multicenter, retrospective, single-arm observational study included patients aged ≥18 years who underwent PCI using at least one Optima NC PTCA balloon catheter at four cardiology centers in India between January and June 2024. Eligible patients had ≥80% coronary artery stenosis requiring PCI. The primary endpoint was procedural success, defined as successful balloon delivery, inflation, and retrieval without major procedural complications, together with achievement of final Thrombolysis in Myocardial Infarction (TIMI) grade III flow. Secondary endpoints included device success, operator-assessed device performance characteristics, and clinical outcomes through three months of follow-up. Results Of 216 patients screened, 196 (90.7%) were included in the final analysis, and 20 (9.3%) were excluded because of incomplete clinical or procedural information. The mean age was 59.20 ± 11.74 years, and 151 (77.0%) patients were male. Acute coronary syndrome was present in 191 (97.45%) patients, and multivessel disease in 111 (56.63%). The left anterior descending artery (LAD) was the most frequently treated vessel (112 (57.14%) patients). Procedural success was achieved in 193/196 (98.5%) procedures, while final TIMI grade III flow was achieved in 196/196 (100%) procedures. Device success was achieved in 193/196 (98.5%) procedures. No major adverse cardiac events (MACE) were reported during the index procedure or at discharge. During follow-up, one myocardial infarction (0.51%) was reported at one month, while one target lesion failure (TLF) (0.51%) and one cardiac death (0.51%) were reported at three months. Conclusion In this multicenter real-world cohort, the Optima NC PTCA balloon catheter demonstrated high observed procedural and device success, with favorable operator-assessed performance and few clinical events during short-term follow-up. Given the retrospective single-arm design and absence of a comparator, these findings are descriptive and do not establish comparative efficacy, superiority, or long-term safety. Prospective comparative studies with larger populations and longer follow-up are warranted to further characterize the clinical performance of the device.
Related
- Modified interventional retrieval of a balloon with transverse rupture during percutaneous transluminal angioplasty of a vascular access： a case report
- Hypertrophic obstructive cardiomyopathy complicated by severe midventricular obstruction treated with percutaneous transluminal septal myocardial ablation using simultaneous contrast imaging with left ventriculography and coronary angiography: a case report
- Prognostic value of chronic total occlusion complexity scoring systems beyond procedural planning: a comparative analysis of five contemporary scores in patients undergoing chronic total occlusion percutaneous coronary intervention
- Dual antiplatelet therapy duration after percutaneous coronary intervention with contemporary drug-eluting stents: A systematic review and network meta-analysis of randomized trials
- Vascular access options for complex high-risk indicated percutaneous coronary interventions: contemporary strategies, trade-offs, and practical algorithms
BibTeX
@article{narain2026clinical,
title = {{Clinical Performance and Safety of the Optima Non-compliant Percutaneous Transluminal Coronary Angioplasty Balloon in Contemporary Percutaneous Coronary Intervention: A Multicenter Real-World Study.}},
author = {Sujeet Narain and Chirag Jagdish Parikh and Anup Ashok Pusate and Anuj Sarda and Hitendra Bhagwatkar},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116826},
url = {https://europepmc.org/article/MED/42927340},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical Performance and Safety of the Optima Non-compliant Percutaneous Transluminal Coronary Angioplasty Balloon in Contemporary Percutaneous Coronary Intervention: A Multicenter Real-World Study.
AU - Sujeet Narain
AU - Chirag Jagdish Parikh
AU - Anup Ashok Pusate
AU - Anuj Sarda
AU - Hitendra Bhagwatkar
PY - 2026
DA - 2026/09/24
JO - Cureus
DO - 10.7759/cureus.116826
UR - https://europepmc.org/article/MED/42927340
AB - Background Non-compliant (NC) balloon catheters are widely used during percutaneous coronary intervention (PCI) for lesion preparation and stent optimization because they allow controlled high-pressure dilation. However, real-world clinical data describing the procedural performance and short-term clinical outcomes of NC balloon catheters across diverse patient and lesion characteristics remain limited. This study evaluated the observed procedural performance, device performance characteristics, and short-term clinical outcomes associated with the use of the Optima NC non-compliant percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (Translumina Therapeutics Private Limited, New Delhi, India) during routine PCI. Methods This multicenter, retrospective, single-arm observational study included patients aged ≥18 years who underwent PCI using at least one Optima NC PTCA balloon catheter at four cardiology centers in India between January and June 2024. Eligible patients had ≥80% coronary artery stenosis requiring PCI. The primary endpoint was procedural success, defined as successful balloon delivery, inflation, and retrieval without major procedural complications, together with achievement of final Thrombolysis in Myocardial Infarction (TIMI) grade III flow. Secondary endpoints included device success, operator-assessed device performance characteristics, and clinical outcomes through three months of follow-up. Results Of 216 patients screened, 196 (90.7%) were included in the final analysis, and 20 (9.3%) were excluded because of incomplete clinical or procedural information. The mean age was 59.20 ± 11.74 years, and 151 (77.0%) patients were male. Acute coronary syndrome was present in 191 (97.45%) patients, and multivessel disease in 111 (56.63%). The left anterior descending artery (LAD) was the most frequently treated vessel (112 (57.14%) patients). Procedural success was achieved in 193/196 (98.5%) procedures, while final TIMI grade III flow was achieved in 196/196 (100%) procedures. Device success was achieved in 193/196 (98.5%) procedures. No major adverse cardiac events (MACE) were reported during the index procedure or at discharge. During follow-up, one myocardial infarction (0.51%) was reported at one month, while one target lesion failure (TLF) (0.51%) and one cardiac death (0.51%) were reported at three months. Conclusion In this multicenter real-world cohort, the Optima NC PTCA balloon catheter demonstrated high observed procedural and device success, with favorable operator-assessed performance and few clinical events during short-term follow-up. Given the retrospective single-arm design and absence of a comparator, these findings are descriptive and do not establish comparative efficacy, superiority, or long-term safety. Prospective comparative studies with larger populations and longer follow-up are warranted to further characterize the clinical performance of the device.
SN - 2168-8184
ER -